- Short communication
- Open Access
Amyloid PET quantification using low-dose CT-guided anatomic standardization
EJNMMI Research volume 11, Article number: 125 (2021)
Centiloid (CL) scaling has become a standardized quantitative measure in amyloid PET because it facilitates the direct comparison of results across institutions, even when different analytical methods or tracers are used. Standard volumes of interest must be used to calculate the CL scale after the anatomic standardization of amyloid PET images using coregistered MRI; if the MRI is unavailable, the CL scale cannot be accurately calculated. This study sought to determine the substitutability of low-dose CT, which is used to correct PET attenuation in PET/CT equipment, by evaluating the measurement accuracy when low-dose CT is used as an alternative to MRI in the calculation of the CL scale. Amyloid PET images obtained using 18F-flutemetamol from 24 patients with possible or probable Alzheimer’s disease were processed to calculate the CL scale using 3D T1-weighted MRI and low-dose CT of PET/CT. CLMRI and CLCT were, respectively, defined as the use of MRI and CT for anatomic standardization and compared. Regional differences in the CT-based and MRI-based standardized anatomic images were also investigated. Trial registration: Japan Registry of Clinical Trials, jRCTs031180321 (registered 18 March 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031180321).
A Bland–Altman plot showed that CLCT was slightly but significantly underestimated (mean ± standard deviation, − 1.7 ± 2.4; p < 0.002) compared with CLMRI. The 95% limits of agreement ranged from − 2.8 to − 0.7. Pearson correlation analysis showed a highly significant correlation of r = 0.998 between CLCT and CLMRI (p < 0.001). The linear regression equation was CLMRI = 1.027 × CLCT + 0.762. In a Bland–Altman plot, Spearman correlation analysis did not identify a significant association between the difference in CLMRI versus CLCT and CL load (ρ = − 0.389, p = 0.060). This slight underestimation of CLCT may derive from slightly higher uptake when the cerebellum is used as a reference area in CT-based anatomically standardized PET images versus MRI-based images.
Low-dose CT of PET/CT can substitute for MRI in the anatomic standardization used to calculate the CL scale from amyloid PET, although a slight underestimation occurs.
In clinical practice for dementia, amyloid PET increases the certainty of Alzheimer's disease (AD) and non-AD diagnosis . In many settings, the binary classification of positive and negative amyloid PET findings is based on visual interpretation. Equivocal findings are thus inevitable and lead to interrater variability in visual interpretation  because raters have their own experience and potential internal criteria. In addition, in our previous multicenter study using 18F-flutemetamol , disagreement between two raters was observed in 9% of cases. Equivocal findings should be avoided when determining the indication for the disease-modifying drugs currently in development. Accordingly, quantitative analysis has been proposed as an adjunct to visual interpretation .
The quantitative analysis of amyloid PET has widely applied the standardized uptake value ratio (SUVR). However, SUVR values vary not only according to the target and reference regions used, but also according to the particular amyloid tracer used. This variability can be resolved through a Centiloid (CL) scaling process that standardizes the quantitative amyloid imaging measures by standardizing the outcome of each analytical method or PET ligand to a scale from 0 to 100 . The CL scaling method can facilitate the direct comparison of results across institutions, even when different analytical methods or tracers are used, and may enable cutoffs for amyloid positivity to be clearly defined. A positive relationship of the CL scale cutoff with pathological findings has been found [6,7,8,9], and it is expected that the clinical value of the CL scale will continue to increase. When determining the CL scale, it is necessary to follow the method advocated by the Global Alzheimer’s Association Interactive Network (GAAIN, http://www.gaain.org/centiloid-project). Because highly accurate anatomic standardization to standard Montreal Neurological Institute (MNI) space is required to use standard volumes of interest (VOIs) supplied from GAAIN to calculate the CL scale converted from SUVR, anatomic standardization of amyloid PET images should be performed using coregistered MRI obtained around the same period. For this MRI, the use of a three-dimensional (3D) T1-weighted image that covers the whole brain is recommended. However, if a 3D T1-weighted image is not available, the CL scale cannot be accurately calculated. As an alternative, Pressoto et al.  reported that anatomic standardization of amyloid PET can be performed with low-dose CT, which is used to correct PET attenuation in PET/CT equipment. According to their report, the difference between the SUVR values measured by anatomic standardization using MRI and low-dose CT is only 0.01 ± 0.03 (mean ± standard deviation) and is thus negligible. The purpose of the present study was to establish the substitutability of low-dose CT of PET/CT proposed by Pressoto et al. by verifying the measurement accuracy at the global and regional levels when low-dose CT is used as an alternative to MRI in the calculation of the SUVR and CL scales in amyloid PET.
Materials and methods
The study participants comprised 24 patients (15 men and 9 women; age range 48–90 years) enrolled in a previous multicenter study . They were recruited from an outpatient memory clinic of the National Center of Neurology and Psychiatry, Japan. The participants had a Mini-Mental State Examination score of 19.7 ± 4.6 and a global Clinical Dementia Rating of 0.8 ± 0.4. According to National Institute on Aging and the Alzheimer’s Association criteria , 10 and 14 patients were diagnosed as having possible and probable AD, respectively.
Each subject received an intravenous injection of 215 ± 33 MBq of 18F-flutemetamol (Vizamyl, Nihon Medi-Physics). All PET acquisitions were performed using a hybrid PET/CT Biograph 16 True-point scanner (Siemens Healthineers, Erlangen, Germany). After positioning, a low-dose CT scan (kVp, 130 keV; current, 40 mA; rotation time, 1.0 s; table feed per rotation, 7.2 mm; spiral pitch factor, 0.75) was acquired to be used for the attenuation correction of the PET data. Images were reconstructed using the “H10s very smooth” kernel, a 30.0-cm reconstruction field of view, and a 2.0-mm slice interval for a resulting voxel size of 0.59 × 0.59 × 2.0 mm3. A 3D-PET acquisition (list mode) was started 61.2 ± 0.8 min after the injection of the tracer and lasted for 20 min. Image reconstruction was performed using a 3D ordered subsets expectation maximization algorithm with the following parameters: image matrix, 168; field of view, 300 mm; subsets, 21; iterations, 4; post-filter (Gaussian), 4-mm FWHM; attenuation correction, CT-based. The resulting voxel size was 2.02 × 2.06 × 2.03 mm3. This low-dose CT protocol delivers a head radiation dose of 0.4 mSv.
The MRI for all patients was performed on an Achieva 3.0-T MR scanner (Philips Medical Systems, Best, The Netherlands) equipped with a 32-channel coil within 42 ± 21 days before the amyloid PET. A volumetric turbo field echo T1-weighted structural sequence (300 sagittal slices; TR, 7.0 ms; TE, 3.4 ms; field of view, 260 × 240 mm; voxel size, 0.7 × 0.7 × 0.6 mm3; flip angle, 10°) was acquired for each subject.
Figure 1 shows the processing pipeline applied to quantitative analysis using SUVR and the 100-point CL scale . This MRI-based pipeline has already been validated  using a GAAIN dataset of 11C-PiB PET images for 34 young control individuals and 45 typical AD patients downloaded from the GAAIN website. In the present study, low-dose CT was also used instead of MRI for anatomic standardization. The CL scale assigns an average value of 0 to high-certainty amyloid-negative subjects and an average of 100 to typical AD patients. First, in this pipeline, the subject MRI or CT was oriented and coregistered to the MNI template (avg152T1.nii). The subject PET was then oriented and coregistered to the coregistered subject MRI or CT. Then, the coregistered subject MRI or CT was warped into MNI space using unified segmentation . These translations were performed using the Statistical Parametric Mapping (SPM) 12 software (https://www.fil.ion.ucl.ac.uk/spm). The parameters of the deformation field in this warping were applied to the coregistered subject PET for anatomic standardization into MNI space. Using the standard VOI in GAAIN, SUVR was calculated from 18F-flutemetamol PET counts in the global cortical target area (GAAIN, CTX VOI) and in the whole cerebellum (GAAIN, WhlCbl VOI) as the reference area. Then, a direct conversion equation (CL = 121.42 × SUVR − 121.16) was applied to convert SUVR to the CL value, as described previously .
In addition, PET-only methods using a mean atlas and an adaptive atlas as a template for anatomic standardization in SPM12 were compared against MRI-based quantification in the same manner as previously reported . These PET templates were generated using the present MRI-based anatomical standardization method from datasets collected from the publicly available GAAIN repository. Positive and negative 18F-flutematamol templates as an adaptive atlas were generated by averaging images from 28 AD patients with a CL scale of 92.0 ± 21.6 and 23 young healthy controls with a CL scale of − 1.0 ± 3.5, respectively. A mean atlas was generated by averaging the images of these AD patients and young healthy controls with a CL scale of 50.1 ± 49.4. The selection of the adaptive atlas for the positive or negative template was based on the amyloid-positive cutoff CL level of 16 in a previous report .
We defined SUVRMRI, SUVRCT, SUVRmPET, and SUVRaPET, as well as CLMRI, CLCT, CLmPET, and CLaPET, based on the use of MRI, CT, mean PET, and adaptive PET for anatomic standardization, respectively.
The endpoint of this study was the measurement accuracy of SUVRCT and CLCT when SUVRMRI and CLMRI were, respectively, regarded as the gold standard.
Concordances between SUVRMRI and SUVRCT, SUVRMRI and SUVRmPET, and SUVRMRI and SUVRaPET and between CLMRI and CLCT, CLMRI and CLmPET, and CLMRI and CLaPET were assessed using Bland–Altman plots and Pearson correlation estimates. In the Bland–Altman plot of SUVR and CL, we used Spearman correlation analysis to examine whether there were associations between the difference in SUVRMRI versus SUVRCT and SUVR load and between the difference in CLMRI versus CLCT and CL load. Spearman correlation analysis was also performed for SUVR and CL obtained from PET-only methods. SUVR and CL and their standard deviations were computed with mean absolute differences and limits of agreement. These statistical tests were performed using JMP ver. 16 (SAS Institute). In addition, to investigate regional differences in the CT-based and MRI-based standardized amyloid PET images, a paired t-test was applied to these images on a voxel basis after smoothing with an 8-mm FWHM Gaussian kernel using SPM12. Results were considered significant at p < 0.001 with an extent threshold of 300 voxels without multiple comparisons.
Figure 2 shows the standardized MRI, CT, and amyloid PET images in MNI space in a subject, along with the three corresponding images in native space. When compared with SUVRMRI and CLMRI using a Bland–Altman plot (Fig. 3a, d), SUVRCT and CLCT were slightly but significantly underestimated (− 0.01 ± 0.02 and − 1.7 ± 2.4, respectively; p < 0.002). The 95% limits of agreement ranged from − 0.02 to − 0.01 for SUVR and from − 2.8 to − 0.7 for CL. Probable AD patients showed greater underestimation of SUVRCT and CLCT (− 0.02 ± 0.02 and − 2.4 ± 2.7, respectively; p < 0.003) compared with underestimation of SUVRCT and CLCT in possible AD patients (− 0.01 ± 0.01 and − 0.8 ± 1.6, respectively; p = 0.08). Pearson correlation analysis (Fig. 3g, j) showed a highly significant correlation of r = 0.998 between SUVRCT and SUVRMRI (p < 0.001). The linear regression equation was SUVRMRI = 1.027 × SUVRCT − 0.020. CLCT also showed a highly significant correlation of r = 0.998 with CLMRI (p < 0.001). The linear regression equation was CLMRI = 1.027 × CLCT + 0.762.
Compared with SUVRMRI and CLMRI using a Bland–Altman plot (Fig. 3b, e), SUVRmPET and CLmPET were significantly underestimated (− 0.04 ± 0.10 and − 5.1 ± 11.7, respectively; p < 0.05). The 95% limits of agreement ranged from − 0.08 to 0.0 for SUVR and from − 9.8 to − 0.4 for CL. Pearson correlation analysis (Fig. 3h, k) showed a significant correlation of r = 0.971 between SUVRmPET and SUVRMRI and between CLmPET and CLMRI (p < 0.001).
Compared with SUVRMRI and CLMRI using a Bland–Altman plot (Fig. 3c, f), SUVRaPET and CLaPET showed a tendency for overestimation (0.01 ± 0.09 and 1.6 ± 10.3, respectively; p > 0.2). The 95% limits of agreement ranged from − 0.02 to + 0.05 for SUVR and from − 2.5 to + 5.8 for CL. Pearson correlation analysis (Fig. 3i, l) showed a significant correlation of r = 0.975 between SUVRaPET and SUVRMRI and between CLaPET and CLMRI (p < 0.001).
In a Bland–Altman plot, Spearman correlation analysis failed to identify a significant association between the difference in SUVRMRI versus SUVRCT and SUVR load (ρ = − 0.379, p = 0.051) or between the difference in CLMRI versus CLCT and CL load (ρ = − 0.389, p = 0.060). On the other hand, Spearman correlation analysis revealed a significant association between the difference in SUVRMRI versus SUVRmPET and SUVR load (ρ = − 0.713, p < 0.001), between the difference in CLMRI versus CLmPET and CL load (ρ = − 0.702, p < 0.001), between the difference in SUVRMRI versus SUVRaPET and SUVR load (ρ = 0.515, p < 0.001), and between the difference in CLMRI versus CLaPET and CL load (ρ = 0.515, p < 0.001).
Paired t tests performed using SPM12 (Fig. 4; Table 1) found that the brainstem exhibited the biggest differences in uptake between the CT-based and MRI-based standardized PET images. Higher uptake of CT-based standardized PET images than MRI-based PET images was observed within the whole cerebellar VOI. In the supratentorial area, most of the statistically significant differences in uptake between the CT-based and MRI-based standardized PET images were found outside of the global cortical target region VOI.
This study confirmed that low-dose CT of PET/CT can substitute for MRI in the anatomic standardization performed to calculate the CL scale from amyloid PET. The average difference between SUVRCT and SUVRMRI was only 0.01, which was the same as in a previous study . The difference in the CL scale between CLCT and CLMRI was also only 1.7 on average. CT acquired at exactly the same time as amyloid PET enables accurate coregistration of CT and PET. When MRI is unavailable, simultaneously obtained low-dose CT of PET/CT can provide accuracy nearly equal to that of MRI for CL scale calculation. This simultaneity can avoid the misregistration of MRI and PET when there is a substantial delay between modalities during which brain atrophy progresses in AD patients. On the other hand, the concordance between the SUVR and CL scales determined by PET-only methods and those determined by an MRI-based method was much lower than that between the SUVR and CL scales determined by a CT-based method and those determined by an MRI-based method.
Several studies have reported anatomic standardization using the amyloid PET template alone without MRI. However, the single-atlas PET template-based method provides a less accurate definition of cortical gray matter regions compared with the MRI-based method . This inaccuracy may result from intensity-based standardization using a PET template. The high white matter and low gray matter uptake in amyloid-negative individuals tends to slightly shift the target’s white matter toward the single-atlas gray matter, leading to increased sampling of the white matter and an overestimation of the neocortical uptake. Mean cortical SUVRs in healthy controls were 1.11 and 1.27 on average using the single-atlas PET template and MRI-based method, respectively . Similarly, the low white matter and high gray matter uptake in amyloid-positive individuals tends to slightly shift the target’s gray matter toward the single-atlas white matter, leading to decreased sampling of the gray matter and an underestimation of the neocortical uptake. Mean cortical SUVRs in AD patients were 1.76 and 1.74 on average using the single-atlas PET template and MRI-based method, respectively . Consequently, the single-atlas PET template-based method gives a lower discrimination performance between cognitively normal individuals and AD patients compared with the MRI-based method . The present PET-alone study using a mean atlas also revealed much greater underestimation of the SUVR and CL scales in comparison with the CT-based method. Moreover, this difference became greater as the SUVR or CL scale increased.
To overcome the drawback of the single-atlas PET template-based method, the application of a multi-atlas PET template to the anatomic standardization has been proposed [14, 17]. Computation of similarities between the anatomically standardized image of a patient and the multi-atlas templates automatically chooses the appropriate PET template. This multi-atlas approach reduces the overall error from 5.6% using a single-atlas to 2.7% in neocortical SUVR estimation compared with the MRI-based method . Although this multi-atlas approach may improve the accuracy of anatomic standardization, it might not be able to cope with amyloid PET images with asymmetrical accumulation between the left and right hemispheres. This asymmetry causes interhemispheric differences in the accuracy of the registration to the PET template. In the present PET-alone method using an atlas adapted to a positive or negative template, there was a marked tendency for overestimation on the higher SUVR and CL scales. From these considerations, structural images may be necessary for precise anatomic standardization in amyloid PET.
CT-based standardization showed slightly but significantly lower SUVR and CL scales compared with MRI-based standardization. Direct comparison indicated that CT evaluation exhibits increased uptake in bilateral cerebellar hemispheres compared with MRI. This slightly increased uptake of the cerebellar hemisphere in a reference area may lead to a slight decrease in SUVR and CL in a target area of the cerebral cortex in CT-based standardization. This may be due to the lower accuracy of anatomic standardization by low-dose CT in the posterior cranial fossa compared with MRI.
There are some limitations in this study. First, we did not study the influence of the CT image quality on the anatomic standardization. Future studies will need to assess both the lower dose limit at which the algorithm still performs correctly with reduced current and whether the use of diagnostic-quality CT provides improvements. Second, the SPM results showed a remarkable difference in brain stem uptake between MRI-based and CT-based standardized images. Accordingly, the reference region should not be located in the brain stem, including the pons, in a CT-based method. Third, we applied this low-dose CT-guided method to only possible and probable AD patients with mild or moderate cognitive impairment. However, the greater difference in the SUVR and CL scales between the MRI-based and CT-based methods in probable AD patients than in AD patients suggests that future studies are needed to validate this method for the full spectrum of AD with varying levels of atrophy. Fourth, this approach should be further validated for the measurement of CL scales using other amyloid PET tracers, such as 11C-PiB, 18F-florbetapir, 18F-florbetaben, and 18F-NAV4694.
This study proposed the use of low-dose CT of PET/CT for calculating the CL scale from amyloid PET. CL scales based on low-dose CT show a highly significant positive correlation with those based on MRI, regardless of the degree of amyloid accumulation in possible and probable AD patients with mild or moderate cognitive impairment. A key advantage of the use of low-dose CT is the simultaneous acquisition of PET and CT. This method would be applicable to subjects who are unable to undergo MRI.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Leuzy A, Savitcheva I, Chiotis K, Lilja J, Andersen P, Bogdanovic N, et al. Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur J Nucl Med Mol Imaging. 2019;46:1276–86. https://doi.org/10.1007/s00259-019-04297-5.
Hosokawa C, Ishii K, Kimura Y, Hyodo T, Hosono M, Sakaguchi K, et al. Performance of 11C-Pittsburgh Compound B PET binding potential images in the detection of amyloid deposits on equivocal static images. J Nucl Med. 2015;56:1910–5. https://doi.org/10.2967/jnumed.115.156414.
Matsuda H, Ito K, Ishii K, Shimosegawa E, Okazawa H, Mishina M, et al. Quantitative evaluation of 18F-flutemetamol PET in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study. Front Neurol. 2021;11:578753. https://doi.org/10.3389/fneur.2020.578753.
Collij LE, Konijnenberg E, Reimand J, Kate MT, Braber AD, Alves IL, et al. Assessing amyloid pathology in cognitively normal subjects using 18F-flutemetamol PET: comparing visual reads and quantitative methods. J Nucl Med. 2019;60:541–7. https://doi.org/10.2967/jnumed.118.211532.
Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1–15. https://doi.org/10.1016/j.jalz.2014.07.003.
Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11:27. https://doi.org/10.1186/s13195-019-0478-z.
La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 2019;15:205–16. https://doi.org/10.1016/j.jalz.2018.09.001.
Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabli O, et al. Comparison of 18 F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL ® approaches: validation against histopathology. Alzheimers Dement. 2019;15:807–16. https://doi.org/10.1016/j.jalz.2019.02.005.
Amadoru S, Doré V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease. Alzheimers Res Ther. 2020;12:22. https://doi.org/10.1186/s13195-020-00587-5.
Presotto L, Iaccarino L, Sala A, Vanoli EG, Muscio C, Nigri A, et al. Low-dose CT for the spatial normalization of PET images: a validation procedure for amyloid-PET semi-quantification. Neuroimage Clin. 2018;20:153–60. https://doi.org/10.1016/j.nicl.2018.07.013.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005.
Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839–51. https://doi.org/10.1016/j.neuroimage.2005.02.018.
Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8:107. https://doi.org/10.1186/s13550-018-0456-7.
Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36(Suppl 1):S159–66. https://doi.org/10.1016/j.neurobiolaging.2014.04.033.
Edison P, Carter SF, Rinne JO, Gelosa G, Herholz K, Nordberg A, et al. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neuroimage. 2015;70:423–33. https://doi.org/10.1016/j.neuroimage.2012.12.014.
Saint-Aubert L, Nemmi F, Péran P, Barbeau EJ, Payoux P, Chollet F, et al. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging. 2014;41:836–43. https://doi.org/10.1007/s00259-013-2656-8.
Tsubaki Y, Akamatsu G, Shimokawa N, Katsube S, Takashima A, Sasaki M, et al. Development and evaluation of an automated quantification tool for amyloid PET images. EJNMMI Phys. 2020;7:59. https://doi.org/10.1186/s40658-020-00329-4.
We thank the staff of the Department of Radiology, National Center of Neurology and Psychiatry, for their contribution to the performance of the study.
This research was supported by Nihon Medi-Physics Co., Ltd.
Ethics approval and consent to participate
This study was reviewed and approved by the Certified Clinical Research Review Board at the National Center of Neurology and Psychiatry. This study was registered in the Japan Registry of Clinical Trials (jRCTs, 031180321). The participants provided written informed consent to participate in this study.
Consent for publication
Informed consent was obtained from all individual participants included in the study.
H. Matsuda has received a research grant from Nihon Medi-Physics Co., Ltd. All other authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Matsuda, H., Yamao, T., Shakado, M. et al. Amyloid PET quantification using low-dose CT-guided anatomic standardization. EJNMMI Res 11, 125 (2021). https://doi.org/10.1186/s13550-021-00867-7
- Alzheimer’s disease
- Amyloid imaging
- Positron emission tomography
- Magnetic resonance imaging
- Computed tomography
- Centiloid scale